Dasatinib and the Risk of Pulmonary Arterial Hypertension

Published Online: Friday, October 21, 2011
Follow Pharmacy_Times:
In this podcast, Jennifer Shepherd, a pharmacist in the FDA’s Division of Drug Information, discusses the increased risk of pulmonary arterial hypertension associated with Sprycel (dasatinib), a drug indicated to treat leukemia.

To access the podcast, click here.
Related Articles
Providing prescriptions when patients are discharged from the hospital after a stroke improves medication adherence, the results of a study suggest.
Updated REMS attempts to stem the flow of extended-release, long-acting opioids to addicts while ensuring patients in severe pain retain access.
Latest Issues
$auto_registration$